Background: Serum CA125 (sCA125) was recently reported to be of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma (NHL). This report aims to investigate the prognostic value of a new serologic index combining sCA125 and LDH serum levels.
Introduction
CA125 is an antigenic determinant recognized by monoclonal antibody CA125 raised against a serous ovarian cancer cell line. This marker is commonly used in the monitoring of epithelial ovarian cancer [1, 2] . The serum level may be increased in many other malignant and non-malignant diseases [3] [4] [5] [6] .
Non-Hodgkin's lymphomas (NHLs) are an heterogeneous group of lymphoproliferative malignant diseases with differing patterns of behavior and response to treatment [7] . However the majority of patients die from disease progression, regardless of histological sub-type. The identification of pre-treatment variables that correlate with response to therapy, duration of remission and survival should be lead to the rational selection of initial therapy and, in particular, of alternative therapy for patients likely to die either from treatment failure or treatment-related toxicity.
A variety of pretreatment clinical characteristics have been identified as associated with the survival of patients with aggressive NHLs: age at diagnosis, systemic (B) symptoms, performance status, serum LDH, serum p 2 microglobulin (p^m), number of nodal and extranodal sites of disease, tumor bulk, and the distinction between localized and advanced-stage disease [8] [9] [10] [11] . Clinical pretreatment variables have been used to develop prognostic factor models predictive of an individual patient's risk of death [12] [13] [14] [15] [16] [17] [18] . The International Non-Hodgkin's Lymphoma Prognostic Index (IPI) is widely accepted to-day as the standard tool for determining the prognosis of patients with high-grade NHL [19] .
In contrast, prognostic factors are not well established in low-grade non-Hodgkin's Lymphoma. Although many studies have been published on prognostic factors in low-grade lymphomas [20] [21] [22] [23] [24] [25] [26] , and some prognostic systems have been proposed [27] [28] [29] [30] , there is no easy and widely accepted prognostic system. Serum CA125 was recently reported by Lazzarino et al. [31] to be of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma. However, few reports have focused on this in malignant lymphoma [32] [33] [34] [35] .
In this analysis of 137 patients with previously untreated NHL, we demonstrated that an elevated level of CA125 is a significant prognostic factor for complete remission rate and survival, and we propose a new biological prognostic index in combination with LDH level.
Patients and methods

Patients
In order to assess the potential prognostic value of CA125 serum level in NHL, since 1993 we have measured the initial serum CA125 (sCA125) level at diagnosis in 137 previously untreated patients with NHL. sCA125 was measured by radioimmunoassay (CIS international*). Normal values were considered to be below 25 IU/1, Of the 137 adults with malignant lymphoma classified according to the international working formulation [36] , 46 were considered as low grade, 17 as mantle-cell lymphoma and 74 as aggressive lymphoma, 63 of whom had histologically-proven diffuse large-cell lymphoma. Stage was determined using the Ann Arbor staging system [37] .
Pretreatment evaluation
Pretherapy evaluation included history and physical examination with assessment of performance status using the WHO performance status scale; blood cell count with differential leukocyte count, renal and liver function tests, sCA125, serum lactate dehydrogenase (LDH), p 2 m > calcium, uric acid and blood glucose measurement; chest radiography; computed tomography of the chest, abdomen and pelvis; and unilateral iliac crest bone marrow biopsy. Assessment of the CSF was performed if clinically indicated, if NHL was leukemic or if the paranasal sinus, Waldeyer's ring, testis or breast was involved or if the patient had immunoblastic lymphoma.
Treatment
All patients were treated according to the GOELAMS group protocols. All patients with aggressive NHL received doxorubicin-based chemotherapy regimens. For low-grade NHL the treatment used was monochemotherapy in 11 cases, regimens without anthracycline in 18 cases and regimens with anthracycline in 34 cases.
In the aggressive NHL patients with paranasal sinus, Waldeyer ring, epidural, breast or testis involvement and/or immunoblastic lymphoma and/or in leukemic phase received six doses of intrathecal chemoprophylaxis with 15 mg methotrexate and 40 mg cytarabine by lumbar puncture.
Assessment of response
Patients were usually restaged after four or six months of treatment. Response to treatment was evaluated by reexamination of all pretherapy abnormalities. Complete remisssion (CR) was defined as the disappearance of all clinical and radiographic evidence of tumor and partial response (PR) was defined as a 50% or greater reduction in the sum of the products of the perpendicular diameters of all measurable sites of tumor. All other patients were classified as nonresponders.
Prognostic factors
The factors evaluated for potential prognostic significance included sex, age, stage, performance status, presence of B symptoms, histologic subtypes, bone marrow involvement, number of extranodal sites of disease, bulky tumor (> 10 cm in diameter), erythrocyte sedimentation rate, LDH level, and sCA125 and p 2 m levels.
Statistical analysis
Analysis was based on patient status on January 1, 1999. Survival and relapse-free survival (RFS) curves were calculated according to the Kaplan-Meier method [38] , and the log-rank test [39] was used to compare survival curves. Overall survival (OS) was calculated from diagnosis to death and RFS from diagnosis to date of first relapse. Cox regression [40] was used to evaluate various prognostic factors simultaneously, variables with a P-value < 0.1 at univariate analysis were included in the multivariate model. Categorial variables were compared using the chi-square tests. The Mann-Whitney test was used to compare continuous numeric data. The logistic regression model was used to perform multivariate analysis to identify variables predictive of CR. Statistical analysis was performed using BMDP statistical software [41] . (Table 1) The median age of patients was 59 years (range 16-89). There were 68 men and 69 women. Histology typing was based on the Working Formulation [36] : 63 were considered to be low-grade NHL (17 mantle-cell lymphoma) and 74 to be intermediate or high-grade NHL, 63 of whom had histologically-proven diffuse large-cell lymphoma.
Results
Patient characteristics
According to Ann Arbor staging, the majority of patients (65.7%) presented with generalized disease (stage III, 20 patients; stage IV, 70 patients). Of the stage IV patients 39 had bone marrow involvement and 28 had more than 1 extranodal site involved. Sixteen patients had pleural, pericardial, or peritoneal effusion. B symptoms were present at diagnosis in 28 patients (20%) and bulky disease, defined as tumoral mass more than 10 cm, in 31 cases (23%).
The separation levels used for CA125, LDH and p 2 m in our institution were 25 IU/1, 300 IU/1 and 3 mg/1, respectively. The CA125 serum level was high in 59 patients (43%), LDH level was elevated in 58 patients of 134 tested and p 2 m level was elevated in 23 of 105 patients evaluated (22%). In patients with histologically-proven low-grade NHL 27 of 63 (44%), 14 of 62 (23%) and 10 of 48 (21%) had increased sCA125, LDH and p 2 m levels, respectively. LDH level was more often increased in intermediate or high-grade NHL, (44 of 72; 61%) than sCA125 (32 of 74; 43%) or p 2 m (13 of 54; 23%).
Correlation with Ann Arbor staging and tumor burden
As shown in Table 2 at univariate analysis, high CA125 serum levels were significantly associated with Ann Arbor stage (P = 0.0008), bulky disease (P = 0.0016), number of extranodal sites (P = 0.008), presence of B symptoms {P = 0.0004), bone marrow involvement (P -0.006), performance status (P = 0.0019) and effusions (P = 0.0001). When we compared with the other biological markers, high LDH serum levels were not significantly associated with the number of extranodal sites (P = 0.6) or bone marrow involvement (P -0.15); high P 2 m serum levels were not significantly associated with the number of extranodal sites (P = 0.1) or the presence of B symptoms {P -0.34). Abbreviations: N -normal value; A abnormal value. The total number of patients for each variable is not 137 because some variables were not known for all the patients.
Response to therapy and prognostic indicators of response to treatment
Of 137 patients, 131 were assessable for response to induction chemotherapy. The CR rate was 69%, the remaining patients achieving either partial remission (20 patients), or stable disease or progression (21 patients) ( Table 3 ). The CR rate was lower in patients with elevated sCA125 levels compared with those with low sCA125 levels (82% vs. 39%; P = 1 x l(T 6 ). CR was not statistically associated with any morphologic subtype. Stage III-IV; bone marrow involvement; increased LDH and sCA125 levels were strongly associated with low CR rate and high PR rate or failure rate {P < 0.0001). p 2 m levels were significantly correlated with a lower CR rate and a higher PR rate (P = 0.001). Bulky tumor was marginally associated with response to treatment (P = 0.05). When all parameters with a P-value less than 0.1 were entered in a logistic regression analysis for response to treatment (complete responders vs. others), only stage, bone marrow involvement, and sCA125 level remained statistically significant. Results were identical if mantle-cell lymphoma patients were not included in the study. Results were identical in the low-grade NHL patients, when only the LDH level remained statically significant (P = 0.003) in the intermediate or high-grade NHL patients.
Overall survival
With a median follow-up of 35 months, the significant univariate biological prognostic parameters for five-year overall survival of all patients were found to be s-LDH level (P < 0.0001), p 2 m level (P = 0.005) and sCA125 level (P = 0.02). When we separated intermediate and high-grade NHL and low-grade NHL, sCA125 was not of prognostic value in the high-grade NHL group (P = 0.63), but was predictive of five-year survival of patients with low-grade NHL (94% vs. 53%; P = 0.0012) (Figure 1 ). Among the clinical prgnostic factors survival was statistically influenced by stage (P = 0.027) and performance status (P = 0.050). In the low-grade NHL patients, variable included in a multivariate regression analysis (P < 0.1) were: stage (I or II vs. Ill or IV), bulky disease (absent vs. present), performance status (0 or 1 vs. 2-4), LDH level (< 1 normal vs. > normal), P 2 m level (<1 normal vs. > normal) and sCA125 (<1 normal vs. > normal). Only sCA125 and LDH levels were independent variables of prognosis ( P < l x 10" 4 ).
Proposition/or a new serologic prognostic index
A prognostic index for survival was then constructed with the two variables, namely, LDH and sCA125 levels. The four categories of increasing risk divided naturally into three broad groups. This grouping consisted of a set of patients at low risk who had normal LDH and normal sCA125 levels. The intermediate-risk group consisted of patients either with normal LDH level and abnormal sCA125, or increased LDH level and normal sCA125. The poor-risk group consisted of patients with inceased LDH and sCA125 levels.
We compared the results with the prognostic index defined in the same manner by combination of LDH and p 2 m levels (Table 3) . For intermediate and highgrade NHLs, the prognostic index using LDH and p 2 m always appeared to be more predictive than the LDH and sCA125 combination, both in terms of response to therapy and survival. However, our new prognostic index appeared to be more predictive of overall survival than The survival curve according to the prognostic index including sCA125 and LDH is shown in Figure 2 . The estimated five-year survival from diagnosis for each prognostic index group was as follows: low-risk 97%, intermediate-risk 67%, and high-risk 22% (P < 10" 5 ). When this new serologic index was included in the multivariate analysis along with the initial variables, the new serologic index including sCA125 and LDH (P < 10~4) was the only independent prognostic parameter for survival and relapse-free survival.
Discussion
Many prognostic factors have been described in aggressive NHL [8] [9] [10] [11] and low-grade NHL [20] [21] [22] [23] [24] [25] [26] . Most of them are pre-treatment clinical variables. At this time, the International Prognostic Index (IPI) is widely used to predict the outcome of patients with aggressive lymphomas. Although many studies have been published on prognostic factors in low-grade lymphomas and some prognostic systems have been proposed, there is not an easy and widely accepted prognostic system for such patients; cellular and molecular features, including tumor cell proliferation, adhesion molecule expression, immunophenotype, karyotype abnormalities and host immune response have recently been linked to survival in NHL [42] . Many biological markers have been described as prognostic factors, mainly in aggressive NHL: thymidine kinase [43] , serum di-acid glycoprotein [44] , serum interleukin 10 [45] , C-reactive protein and interleukin 6 [46] , and TNF-oc [47, 48] . However LDH and p 2 M levels remain the two serological markers which are widely used in aggressive and low-grade NHL. CA125 is a glycoprotein expressed by epithelial ovarian tumors. Its serum levels are commonly used to monitor response to therapy in patients with ovarian carcinoma. Increased serum CA125 levels have also Abbreviations: CR -complete remission; N -normal value; A -abnormal value. The total number of patients for each vanable is not 137 because some vanables were not known for all the patients° Corrected chi-square, b log-rank test. been reported in nongynecologic tumors such as hepatocellular carcinoma and non-small cell lung cancer. Elevated serum CA125 levels have also been reported in patients with non-Hodgkin's lymphoma, especially those with mediastinal or peritoneal involvement. More recently, its role in the initial staging and the monitoring of NHL has been reported [31, 49] . In 1993 we observed that the CA125 serum level which is commonly used in the monitoring of ovarian cancer was increased in some cases of NHL. We therefore decided to investigate the prognostic value of sCA125 as a biological marker in comparison with LDH and P 2 m. We report our results involving 137 patients, 63 with low-grade NHL, and 74 with aggressive lymphoma.
CA125 and LDH were elevated in more than one third of the patients, CA125 was more frequently increased than LDH in low-grade NHL and LDH was more frequently increased in intermediate or high-grade NHL. A good correlation with stage and tumor burden was observed. When we looked at the prognostic value in terms of response rate, CA125, LDH and P2IT1 were found to be prognostic factors. sCA125 was more discriminative than LDH, and far more discriminative than p 2 m. The prognostic value of sCA125 was greater in patients with low-grade than in patients with intermediate or high-grade NHL. sCA125 was also found to be of prognostic value for survival only for low-grade NHL and not for intermediate or high-grade NHL. This prognostic factor was independent of LDH. For low-grade NHL, survival curves (Kaplan-Meier method) demonstrated a significant difference for patients with normal vs. abnormal initial CA125 serum level (log-rank, P = 0.0012), and overall survival was 94%, and 53% at five years, respectively.
We therefore propose a new prognostic serologic index combining LDH serum level and sCA125 level (normal vs. abnormal) for low-grade NHL. This combi-nation can discriminate three groups of patients and was more predictive of OS and RFS than LDH alone or the combination of LDH and P2m. The five-year overall survival rates were 97%, 67% and 22% for low, intermediate and high-risk groups, respectively (log-rank P < 1 x 10~5). This combination is the only parameter predictive of RFS and OS in multivariate analysis.
In conclusion, these results indicate that serum-CA125 level is frequently increased in a subgroup of patients with NHL and correlates with a poor outcome in patients with low-grade NHL. It appears more predictive for this subgroup of patients than (32m and we propose a new serologic prognostic index combining sCA125 and LDH levels in patients with low-grade NHL which has to be confirmed by further studies.
